JP2007506442A5 - - Google Patents

Download PDF

Info

Publication number
JP2007506442A5
JP2007506442A5 JP2006533538A JP2006533538A JP2007506442A5 JP 2007506442 A5 JP2007506442 A5 JP 2007506442A5 JP 2006533538 A JP2006533538 A JP 2006533538A JP 2006533538 A JP2006533538 A JP 2006533538A JP 2007506442 A5 JP2007506442 A5 JP 2007506442A5
Authority
JP
Japan
Prior art keywords
expression
array
cancer
ckap4
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/017215 external-priority patent/WO2004111273A2/en
Publication of JP2007506442A publication Critical patent/JP2007506442A/ja
Publication of JP2007506442A5 publication Critical patent/JP2007506442A5/ja
Pending legal-status Critical Current

Links

JP2006533538A 2003-05-30 2004-05-28 Egfr阻害薬への応答に関する遺伝子発現マーカー Pending JP2007506442A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47490803P 2003-05-30 2003-05-30
PCT/US2004/017215 WO2004111273A2 (en) 2003-05-30 2004-05-28 Gene expression markers for response to egfr inhibitor drugs

Publications (2)

Publication Number Publication Date
JP2007506442A JP2007506442A (ja) 2007-03-22
JP2007506442A5 true JP2007506442A5 (enExample) 2007-07-05

Family

ID=33551513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533538A Pending JP2007506442A (ja) 2003-05-30 2004-05-28 Egfr阻害薬への応答に関する遺伝子発現マーカー

Country Status (6)

Country Link
US (2) US20050164218A1 (enExample)
EP (2) EP1636380A2 (enExample)
JP (1) JP2007506442A (enExample)
AU (2) AU2004248140A1 (enExample)
CA (1) CA2527321A1 (enExample)
WO (1) WO2004111273A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059012A1 (en) * 2002-07-31 2005-03-17 Daniel Afar Diagnosis of ZD1839 resistant tumors
US20050267689A1 (en) * 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
JP4708342B2 (ja) 2003-07-25 2011-06-22 デックスコム・インコーポレーテッド 埋設可能な装置に用いる酸素増大膜システム
WO2005070020A2 (en) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
EP2527460B1 (en) * 2004-05-27 2014-12-24 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
EP3042964A1 (en) 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
ATE477495T1 (de) 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
KR20080014745A (ko) 2005-04-01 2008-02-14 암젠 인코포레이티드 상피세포 성장인자 수용체 유전자 복제 수
EP2083088A3 (en) * 2005-04-07 2009-10-14 Novartis Vaccines and Diagnostics, Inc. Cancer-related genes
KR20080003422A (ko) * 2005-04-14 2008-01-07 메르크 파텐트 게엠베하 종양 조직 내의 egfr 유전자의 증가된 복제수에 기초한항-egfr 항체 치료
KR20080026093A (ko) * 2005-05-04 2008-03-24 유니버시티 오브 사우스 플로리다 암 환자의 치료 반응을 예측하는 방법
EP1913157B2 (en) * 2005-06-28 2016-10-26 Genentech, Inc. Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP1984735B1 (en) * 2006-02-16 2010-10-06 Ventana Medical Systems, Inc. Reagents and methods for cancer prognosis and pathological staging
US20070207467A1 (en) * 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
JP2007252312A (ja) * 2006-03-24 2007-10-04 Japan Health Science Foundation 上皮成長因子受容体−チロシンキナーゼ阻害剤に対する肺ガンの感度測定方法および肺ガン治療剤のスクリーニング方法
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US8024282B2 (en) * 2006-03-31 2011-09-20 Biodesix, Inc. Method for reliable classification of samples in clinical diagnostics using an improved method of classification
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858390B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7858389B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
US7906342B2 (en) 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2007137187A2 (en) 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
US20070281305A1 (en) * 2006-06-05 2007-12-06 Sean Wuxiong Cao Detection of lymph node metastasis from gastric carcinoma
ES2372217T3 (es) * 2006-09-12 2012-01-17 Genentech, Inc. Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
DK2465950T3 (en) 2007-03-13 2017-10-09 Amgen Inc K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY TREATMENT
JP5240739B2 (ja) 2007-04-13 2013-07-17 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
WO2009023172A2 (en) * 2007-08-09 2009-02-19 The Johns Hopkins University Predictions of responsiveness to egfr inhibitors
BRPI0815372A2 (pt) * 2007-08-14 2019-09-24 Hoffmann La Roche marcador preditivo para o tratamento com inibidor do egfr
JP5416107B2 (ja) * 2007-08-14 2014-02-12 エフ.ホフマン−ラ ロシュ アーゲー Egfr阻害剤治療のための予測マーカー
EP2179058A2 (en) * 2007-08-14 2010-04-28 F. Hoffmann-Roche AG Predictive marker for egfr inhibitor treatment
KR20100037638A (ko) * 2007-08-14 2010-04-09 에프. 호프만-라 로슈 아게 Egfr 억제제를 이용한 치료에 대한 예측 마커
KR101169247B1 (ko) * 2007-08-14 2012-08-03 에프. 호프만-라 로슈 아게 Egfr 저해제 처리 마커
WO2009021684A2 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
EP2208066A2 (en) 2007-10-03 2010-07-21 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2694154A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8273534B2 (en) * 2008-05-14 2012-09-25 Genomic Health, Inc. Predictors of patient response to treatment with EGF receptor inhibitors
WO2010015536A1 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
WO2010015535A1 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
WO2010015538A2 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
CN106153918A (zh) * 2008-10-14 2016-11-23 卡里斯Mpi公司 描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶
EP2342355A4 (en) * 2008-10-29 2012-06-27 Beaumont Hospital William PROCESS FOR USE OF BIOMARKERS
CA2743211A1 (en) 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
WO2010064702A1 (ja) * 2008-12-05 2010-06-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー
WO2010099137A2 (en) * 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2011106084A1 (en) * 2010-02-24 2011-09-01 Biodesix, Inc. Cancer patient selection for administration of therapeutic agents using mass spectral analysis
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
EP2542893A2 (en) * 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2012102829A1 (en) 2011-01-28 2012-08-02 Biodesix, Inc. Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ,エルエルシー 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
CA2845179A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
WO2013055530A1 (en) 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013123588A1 (en) * 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
CN103408662A (zh) * 2013-08-15 2013-11-27 浙江农林大学 一种抗蟾皮转胶蛋白-2重组蛋白的鼠抗血清的制备方法
US9211314B2 (en) 2014-04-04 2015-12-15 Biodesix, Inc. Treatment selection for lung cancer patients using mass spectrum of blood-based sample
JP6779858B2 (ja) * 2014-07-29 2020-11-04 ウェルマーカー バイオ カンパニー リミテッド Egfr−標的製剤に対する感受性予測用の新規なバイオマーカー及びその用途
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス, インコーポレイテッド Cd80細胞外ドメインポリペプチドと、がん治療でのそれらの使用
KR102406696B1 (ko) * 2020-06-19 2022-06-08 (주)신테카바이오 약물 민감도 판단을 위한 유전자 검출 방법 및 진단용 조성물
WO2022255401A1 (ja) * 2021-06-03 2022-12-08 国立大学法人 東京大学 Erk-mapk経路の異常な活性化に伴い発現する疾患マーカー

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
PT868519E (pt) * 1995-12-18 2006-05-31 Sugen Inc Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6203993B1 (en) * 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5861278A (en) * 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
CA2271783C (en) * 1996-11-20 2013-04-16 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) * 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6998233B2 (en) * 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6919178B2 (en) * 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
US9534254B1 (en) * 1999-02-02 2017-01-03 Abbott Molecular Inc. Patient stratification for cancer therapy based on genomic DNA microarray analysis
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
AU2001232485A1 (en) * 2000-01-13 2001-07-24 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
WO2001055454A1 (en) * 2000-01-28 2001-08-02 Althea Technologies, Inc. Methods for analysis of gene expression
AU2001251086A1 (en) * 2000-03-31 2001-10-15 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
EP1358349A2 (en) * 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
AU2001280008A1 (en) * 2000-07-21 2002-02-05 Global Genomics Ab A method and an algorithm for mRNA expression analysis
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
AU2002255478A1 (en) * 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7776518B2 (en) * 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
AU2002246970B2 (en) * 2001-01-12 2007-06-14 Yale University Detection of survivin in the biological fluids of cancer patients
US6939670B2 (en) * 2001-03-12 2005-09-06 Monogen, Inc. Cell-based detection and differentiation of lung cancer
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
AU2002351828A1 (en) * 2001-11-05 2003-05-19 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
CN102402650A (zh) * 2001-11-09 2012-04-04 生命技术公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer

Similar Documents

Publication Publication Date Title
US8198024B2 (en) Gene expression markers for colorectal cancer prognosis
ES2821300T3 (es) Predicción de pronóstico para el melanoma de cáncer
JP2014509189A (ja) 結腸ガン遺伝子発現シグネチャーおよび使用方法
JP2024126029A (ja) 循環腫瘍核酸分子のマルチモーダル分析
CN105431738A (zh) 胃癌的预后预测模型的建立方法
CN103403187A (zh) 结肠直肠癌复发的预后特征
KR20180002882A (ko) 유전자 발현 프로파일 및 유방암에 대한 이의 용도
EP2780476B1 (en) Methods for diagnosis and/or prognosis of gynecological cancer
WO2016118670A1 (en) Multigene expression assay for patient stratification in resected colorectal liver metastases
KR20170072685A (ko) 삼중음성유방암의 아형 분류 방법
MX2011006926A (es) Metodos y medios para categorizar una muestra que comprende celulas de cancer colorrectal.
EP1683862B1 (en) Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis
JP2020515264A (ja) 早期膵がんを診断するための方法およびキット
JP2024519082A (ja) 肝細胞がんのdnaメチル化バイオマーカー
US20050287541A1 (en) Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma
Somura et al. A three-gene predictor for early intrahepatic recurrence of hepatocellular carcinoma after curative hepatectomy
WO2023168345A2 (en) Methylated dna markers and assays thereof for use in detecting colorectal cancer
Shimada et al. cDNA microarray analysis of esophageal cancer: discoveries and prospects
CN117265104A (zh) LncRNA生物标志物在结直肠癌诊疗中的应用
CN113957145A (zh) m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用
CN110846417A (zh) 头颈部鳞癌诊治标志物
HK40092784A (zh) 循环肿瘤核酸分子的多模态分析
AU2024237081A1 (en) Methods of developing cancer diagnostic models and uses thereof in developing cancer detection methods
CN104039980A (zh) 精子蛋白作为早期卵巢癌的检测生物标记物
HK1166352A (en) Gene expression markers for colorectal cancer prognosis